Clearside Biomedical Announces Positive Topline Results from Phase 2 Clinical Trial of CLS-TA Used with Eylea in Patients with ...
Primary and Secondary Endpoints Met in 6-month Trial Patients Treated with CLS-TA Achieved Comparable Vision Improvement With Fewer Treatments ALPHARETTA, Ga., May 31, 2018 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical …